11-5-04 11-08-	2001 11-5-04		
Form PTO-1594	U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office		
To the Honorable Commissioner of Patents and Trademarks: F			
1. Name of conveying party(ies):  JPMorgan Chase Bank  Individual(s)  General Partnership  Corporation-State  NY banking corporation  Additional name(s) of conveying party(ies) attached?  Assignment  Merger  Security Agreement  Other  Release and Reassignment	2. Name and address of receiving party(ies)  Name: Endocrine Sciences, Inc.  Internal Address: Suite 100  Street Address: 4509 Freidrich Lane, Bldg. 1  City: Austin State: TX Zip: 78744  Individual(s) citizenship  Association		
Execution Date: 10/29/2004  4. Application number(s) or registration number(s):  A. Trademark Application No.(s) n.a.	(Designations must be a separate document from assignment) Additional name(s) & address( es) attached? Yes No  B. Trademark Registration No.(s)		
Additional number(s) at	<del>,                                    </del>		
Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and registrations involved:		
Attn: Penelope J.A. Agodoa Federal Research Company, LLC 1030 15th Street, NW, Suite 920 Washington, DC 20005 202.783.2700	7. Total fee (37 CFR 3.41)\$  Enclosed  Authorized to be charged to deposit account		
Street Address:	8. Deposit account number:		
City: State: Zip:  DO NOT USE THIS SPACE			
9. Signature.			

11/08/2004 GTUN11 00000019 2642035

01 FC:8521 02 FC:8522

Penelope S. Johnson

Name of Person Signing

Total number of pages including cover sheet, attachments, and document: Mail documents to be recorded with required cover sheet information to:

Commissioner of Patent & Trademarks, Box Assignments

40.00 OP 225.00 OP

Washington, D.C. 20231

11/02/2004

Date

**REEL: 003073 FRAME: 0303** 

Additional Receiving Party:

The Esoterix Center for Infectious Disease, Inc. Suite 100 4509 Freidrich Lane, Bldg. 1 Austin, TX 78744

(a Delaware corporation)

## EXHIBIT A to Trademark Release and Reassignment

Mark	Owner	Registration No.
SHOXDNA DX	Endocrine	2642035
SHOADINA DA	Sciences, Inc.	
		1
	The Esoterix	]
	Center For	1
	Infectious	1
	Disease, Inc.	
THROMBASSURE	Endocrine	2578609
1	Sciences, Inc.	1
	The Esoterix	
1	Center For	i
j	Infectious	<b>\</b>
j	Disease, Inc.	\ \frac{1}{2}
ALLERPRINT	Endocrine	2670154
	Sciences, Inc.	
1		
	The Esoterix	}
1	Center For	j <sup>o</sup>
1	Infectious	
	Disease, Inc.	
ENTRIX	Endocrine	2764033
Ì	Sciences, Inc.	Ì
<b>\</b>		<b>\</b>
1	The Esoterix	1
4	Center For	ļ
ĺ	Infectious	ĺ
HPVIDX	Disease, Inc Endocrine	2714519
III VIDA	Sciences, Inc.	2/14319
1	Belefices, file.	1
Í	The Esoterix	j
į	Center For	[
	Infectious	1
	Disease, Inc	<u> </u>
HPVDETX	Endocrine	2720002
{	Sciences, Inc.	ļ
1		
	The Esoterix	
(	Center For	
	Infectious	
VIRAMAP	Disease, Inc Endocrine	2578622
VIKAIVIAF	Sciences, Inc.	23/0022
(	Sciences, Inc.	
	The Esoterix	
	Center For	
1	Infectious	
1	Disease, Inc	
LYMPHOPLEX	Endocrine	2578608

Trademark Release – Endocrine and Center 60320706

Mark	Owner	Registration No.
	Sciences, Inc.	
	1	l i
	The Esoterix	}
Ì	Center For	}
	Infectious	)
	Disease, Inc	
MEDTRAX	Endocrine	2576168
ESOTERIX	Sciences, Inc.	
LABORATORY	}	1
INFORMATION	The Esoterix	]
TRACKING SYSTEM	Center For	(
	Infectious	( !
	Disease, Inc.	1 1
IMMUNOMETRIX	Endocrine	2529791
	Sciences, Inc.	1
	(	1
	The Esoterix	[
	Center For	
	Infectious	
1	Disease, Inc.	1

Trademark Release -Endocrine and Center 60320706

## TRADEMARK RELEASE AND REASSIGNMENT

THIS TRADEMARK RELEASE AND REASSIGNMENT is made as of October 4, 2004, by JPMorgan Chase Bank, a New York Banking corporation, as Administrative and Collateral Agent ("Agent").

## WITNESSETH:

WHEREAS, Agent, Endocrine Sciences, Inc., a Delaware corporation ("Endocrine") and The Esoterix Center for Infectious Disease, Inc., a Delaware corporation ("Center;" Endocrine and Center are hereinafter referred to collectively as "Borrowers"), were parties to a security agreement dated on or about May 21, 2003 (the "Security Agreement"), pursuant to which Borrowers granted a security interest to Agent in, and a collateral assignment to Agent of, among other things, the trademarks set forth on Exhibit A hereto; and

WHEREAS, the Security Agreement was recorded by the Assignment Division of the United States Patent and Trademark Office on May 23, 2003, at Reel 2741/ Frame 0379; and

WHEREAS, Borrowers have requested that Agent release its security interest in the Trademarks and reassign the same to Borrowers;

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

- 1. Agent hereby releases its security interest in all of Borrower's right, title and interest in and to all of the following:
  - (a) each trademark, trademark registration and trademark application, including, without limitation, the trademarks, trademark registrations (together with any reissues, continuations or extensions thereof) and trademark applications referred to in <a href="Exhibit A">Exhibit A</a> annexed hereto, and all of the goodwill of the business connected with the use of, and symbolized by, each trademark, trademark registration and trademark application;
  - (b) each trademark license and all of the goodwill of the business connected with the use of, and symbolized by, each trademark license; and
  - (c) all products and proceeds of the foregoing, including, without limitation, any claim by Esoterix against third parties for past, present or future (a) infringement or dilution of any trademark or trademark registration including, without limitation, the trademarks and trademark registrations referred to in Exhibit A annexed hereto, the trademark registrations issued with respect to the

Trademark Release –Endocrine and Center 60320706

trademark applications referred in <u>Exhibit A</u> and the trademarks licensed under any trademark license or (b) injury to the goodwill associated with any trademark, trademark registration or trademark licensed under any trademark license.

2. Agent hereby reassigns, grants and conveys to Borrowers, without any representation, recourse or undertaking by Agent, all of Agent's right, title and interest in and to the trademarks, and the goodwill of Borrowers business connected with the use of and symbolized by the trademarks.

- Remainder of Page Intentionally Left Blank – [Signature Page Follows]

Trademark Release – Endocrine and Center 60320706

IN WITNESS WHEREOF, Agent has caused this Release and Reassignment to be duly executed by its duly authorized officer as of the day and year first above written.

JPMORGAN CHASE BANK, a New York Banking corporation, as Administrative and Collateral Agent

Andra Compton

By:

Name:

Title:

Trademark Release -- Endocrine and Center 60320706

## EXHIBIT A to Trademark Release and Reassignment

Mark	Owner	Registration No.
SHOXDNA DX	Endocrine	2642035
SHOADIVA DA	Sciences, Inc.	
		<u> </u>
	The Esoterix	į
	Center For	
	Infectious	1
	Disease, Inc.	}
THROMBASSURE	Endocrine	2578609
· ·	Sciences, Inc.	l
t		
	The Esoterix	
}	Center For	Ì
1	Infectious	
	Disease, Inc.	
ALLERPRINT	Endocrine	2670154
	Sciences, Inc.	ļ
	The Esoterix	]
İ	Center For	(
Į.	Infectious	į
	Disease, Inc.	
ENTRIX	Endocrine	2764033
	Sciences, Inc.	
}		}
}	The Esoterix	}
	Center For	Į
	Infectious	
HPVIDX	Disease, Inc	2714510
HPVIDX	Endocrine	2714519
	Sciences, Inc.	}
	The Esoterix	{
	Center For	
	Infectious	
	Disease, Inc	
HPVDETX	Endocrine	2720002
	Sciences, Inc.	2,20002
ĺ	Belefices, Inc.	
	The Esoterix	
	Center For	
1	Infectious	
}	Disease, Inc	
VIRAMAP	Endocrine	2578622
	Sciences, Inc.	
	The Esoterix	
	Center For	
ł	Infectious	
	Disease, Inc	
LYMPHOPLEX	Endocrine	2578608

Trademark Release –Endocrine and Center 60320706

Mark	Owner	Registration No.
	Sciences, Inc.	
	The Esoterix	4
	Center For	Í
	Infectious	1
	Disease, Inc	
MEDTRAX	Endocrine	2576168
ESOTERIX	Sciences, Inc.	}
LABORATORY		}
INFORMATION	The Esoterix	}
TRACKING SYSTEM	Center For	
	Infectious	ļ
	Disease, Inc.	
IMMUNOMETRIX	Endocrine	2529791
	Sciences, Inc.	
	The Esoterix	
	Center For	
	Infectious	Ì
	Disease, Inc.	1

**RECORDED: 11/05/2004** 

Trademark Release –Endocrine and Center 60320706